701232-67-9

Basic information

• Product Name: Methyl 2-((1s,4s)-4-(4-hydroxyphenyl)cyclohexyl)acetate
• Synonyms: Methyl 2-((1s,4s)-4-(4-hydroxyphenyl)cyclohexyl)acetate;Cyclohexaneacetic acid, 4-(4-hydroxyphenyl)-, Methyl ester, trans-;trans-Methyl 2-[4-(4-hydroxyphenyl)cyclohexyl]acetate
• CAS NO: 701232-67-9
• Molecular Formula: C₁₅H₂₀O₃
• Molecular Weight: 248.3175
• Mol File: 701232-67-9.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 373.6±25.0 °C(Predicted)
• Appearance: /
• Density: 1.095±0.06 g/cm3(Predicted)
• PKA: 10.21±0.30(Predicted)
• CAS DataBase Reference: Methyl 2-((1s,4s)-4-(4-hydroxyphenyl)cyclohexyl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-((1s,4s)-4-(4-hydroxyphenyl)cyclohexyl)acetate(701232-67-9)
• EPA Substance Registry System: Methyl 2-((1s,4s)-4-(4-hydroxyphenyl)cyclohexyl)acetate(701232-67-9)

Safety Data

• Hazardous Substances Data: 701232-67-9(Hazardous Substances Data)

Usage

General Description

Methyl 2-((1s,4s)-4-(4-hydroxyphenyl)cyclohexyl)acetate is a chemical compound with a complex structure. It is a methyl ester derivative of 2-((1s,4s)-4-(4-hydroxyphenyl)cyclohexyl)acetic acid, which is a compound with potential biological activity. The presence of the cyclohexyl and hydroxyphenyl groups in the structure suggests that this compound may have pharmaceutical or therapeutic potential. It is likely being studied for its potential use in medicinal chemistry, drug development, or as a research tool for understanding the role of cyclohexyl and hydroxyphenyl groups in biological processes. Further research is needed to fully understand the properties and potential applications of this chemical compound.

Upstream product

• 701232-66-8 [4-(4-hydroxyphenyl)cyclohexylidene]acetic acid methyl ester 
• 105640-07-1 4-(4-hydroxyphenyl)cyclohexan-1-one 
• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 
• 1245708-05-7 methyl 2-(4-(4-hydroxyphenyl)cyclohexyl)acetate 

Downstream Products

• 701232-68-0 (trans)-methyl 2-(4-(4-(((trifluoromethyl)sulfonyl)oxy)phenyl)cyclohexyl)acetate 
• 1166828-64-3 4-((1r,4r)-4-(2-hydroxyethyl)cyclohexyl)phenol 
• 1109277-50-0 methyl (trans-4-{4-[(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)amino]phenyl}cyclohexyl)acetate 
• 1394002-56-2 methyl (trans-4-{4-[(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl){[4,6-dichloro-2-(methylsulfanyl)-pyrimidin-5-yl]carbonyl}amino]phenyl}cyclohexyl)acetate 
• 1394002-57-3 methyl (trans-4-{4-[{[4,6-dichloro-2-(methylsulfanyl)pyrimidin-5-yl]carbonyl}(2-hydroxyethyl)amino]phenyl}cyclohexyl)acetate 
• 1394002-58-4 methyl (trans-4-{4-[4-chloro-2-(methylsulfanyl)-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl]phenyl}cyclohexyl)acetate 
• 1394002-59-5 methyl (trans-4-{4-[4-amino-2-(methylsulfanyl)-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl]phenyl}cyclohexyl)acetate 
• 1394002-60-8 (trans-4-{4-[4-amino-2-(methylsulfanyl)-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl]phenyl}cyclohexyl)acetic acid 
• 1394002-61-9 (trans-4-{4-[4-amino-2-(methylsulfonyl)-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl]phenyl}cyclohexyl)acetic acid 
• 1398551-70-6 (trans-4-{4-[4-amino-2-(3-methylbutoxy)-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl]phenyl}cyclohexyl)acetic acid trifluoroacetate 
• 701232-69-1 methyl 2-((trans)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclohexyl)acetate 
• 1402466-04-9 methyl 2-((1r,4r)-4-(4-(5-(((R)-1-(2-chlorophenyl)ethoxy)carbonylamino)-1-methyl-1H-pyrazol-4-yl)phenyl)cyclohexyl)acetate 
• 1402465-18-2 2-((1r,4r)-4-(4-(5-(((R)-1-(2-chlorophenyl)ethoxy)carbonylamino)-1-methyl-1H-pyrazol-4-yl)phenyl)cyclohexyl)acetic acid 
• 1245708-73-9 2-((1r,4r)-4-(4-(1-(phenylcarbamoyl)-1H-indol-5-yl)phenyl)cyclohexyl)acetic acid 

Relevant articles and documents

NOVEL BETA-ALANINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT

The present invention relates to a beta-alanine derivative, pharmaceutically acceptable salts thereof, and a pharmaceutical composition including the same as an active ingredient. The novel beta-alanine derivative and pharmaceutically acceptable salts the

Discovery of 6-phenylpyrimido[4,5- B ][1,4]oxazines as potent and selective Acyl CoA: Diacylglycerol acyltransferase 1 (DGAT1) inhibitors with in vivo efficacy in rodents

The discovery and optimization of a series of acyl CoA:diacylglycerol acyltransferase 1 (DGAT1) inhibitors based on a pyrimido[4,5-b][1,4]oxazine scaffold is described. The SAR of a moderately potent HTS hit was investigated resulting in the discovery of phenylcyclohexylacetic acid 1, which displayed good DGAT1 inhibitory activity, selectivity, and PK properties. During preclinical toxicity studies a metabolite of 1 was observed that was responsible for elevating the levels of liver enzymes ALT and AST. Subsequently, analogues were synthesized to preclude the formation of the toxic metabolite. This effort resulted in the discovery of spiroindane 42, which displayed significantly improved DGAT1 inhibition compared to 1. Spiroindane 42 was well tolerated in rodents in vivo, demonstrated efficacy in an oral triglyceride uptake study in mice, and had an acceptable safety profile in preclinical toxicity studies.

4-AMINO-5-OXO-7,8-DIHYDROPYRIMIDO[5, 4 -F] [1, 4] OXAZEPINE COMPOUNDS AS DGAT1 INHIBITORS

Described herein are compounds of formula (I). The compounds of formula (I) act as DGAT1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.